



November 01, 2023

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Sub: Press Release

Dear Sirs,

In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”), please find herewith the presentation on the financials and operational performance of the Company for the quarter and half-year ended September 30, 2023.

The Board Meeting commenced at 10.25 am and concluded at 01:05 pm

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



Investor Presentation

November 2023

Jubilant Ingrevia Limited

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

1. *The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary*
2. *Closing Exchange Rate for USD 1 at Rs 82.66 as on September 30, 2023 and Rs 82.17 as on March 31, 2023*

Company Snapshot and Strategic Outlook - 04

Financial Highlights – Q2 & H1'FY24 - 11

Business Segments Overview - 16

Strategic Initiatives Update - 26

Table of
Contents

Company Overview



Jubilant Bhartia Group – Snapshot- Our Old Version

Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India



Established presence in diversified sectors, e.g., Agro and Pharma Intermediates, CDMO, Therapeutics, Speciality Chemicals, Nutrition, Food Service (QSR), Auto



Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh



10 state of art manufacturing facilities in North America and India across Agro, Pharma & Chemicals



Employs around 46,000 people across the globe with Over 2,400 in North America

Company overview and presence



40+ years of legacy in Chemicals space, started in **1978**



2300+ people with strong **leadership team** with average **25+ years of experience** in Chemicals space



Network of **5 state of art manufacturing facilities** and **3 R&D centres** with 100+ scientists



Trusted partner of choice in India, serving **15 of top 20 Global Pharma** & **7 of top 10 Global Agrochemical companies**



Global player in Pyridine + Beta with 30+ years experience , **Vitamin B3** with 10+ years experience and **Acetic Anhydride** with 40+ years experience



Leading Low Cost provider of Pyridine and its value added derivatives, Vitamin B3 and Acetic Anhydride globally

Strong focus on Environment, Sustainability & Governance



Attained 95 percentile globally (CHM Chemicals) in the S&P Global ESG Indices CSA 2022 (Dow Jones Sustainability Index)



Achieved **GOLD Sustainability rating in EcoVadis**, among the **top 7% of global chemical companies**

Integrated Business Segments

Jubilant Ingrevia Limited

Specialty Chemicals

- Pyridine & Picolines
- Fine Chemicals
- Agro Chemicals
- Microbial Control Solutions
- CDMO

Nutrition & Health Solutions

- Nutrition & Health Ingredients
- Animal & Human Nutrition Health Solutions

Chemical Intermediates


- Acetyls
- Specialty Ethanol

Most of our Businesses segments are backward Integrated which strengthens our cost Leadership




Specialty Chemicals

- **Globally among Top 2** in (Pyridine+Beta);
- **Globally #1** in 18 Pyridine Derivatives



Nutrition & Health Solutions

- **Global top 2** in Vitamin B3
- **Domestic leader** in Vitamin B4



Chemical Intermediates

- **Acetic Anhydride: Globally No. 2** in Merchant Mkt

Strategic Outlook: Pillars of Future Growth



Leading provider of innovative and sustainable solutions in life sciences space globally



Customer Centricity:

Staying relevant with customers and exceeding expectations



Safety as Front and Center:

Zero Risk approach to operations. Safety as part of the core DNA



Innovation and Technology:

Driving forward with innovation to pre-empt customer requirements



Digitally-Enabled, World-Class Operations:

Digital as the key to the future. Embedded within every operating process and facilities. Assuring best balance of cost, efficiency and quality



Environmental, Social, and Governance:

Holding ESG at the forefront of decision making. Raising diversity and inclusion



People Focused:

Best place to work; attract, develop and retain the best talent



Catering to **1500+** customers
With Top 10 customers
constituting 20% of business




134+
products commercialized across
product platforms i.e, Pyridine,
Diketene, Acetyls, Nutrition and
CDMO




Expertise in **35** technology
platforms and multistep
chemistry


**Geographical Mix
HY'FY24 Revenue Split**



**Diverse Industry End-Use
HY'FY24 Revenue Split**



**Business Mix
HY'FY24 Revenue Split**



Executive Leadership Team



Deepak Jain

Chief Executive Officer &
Managing Director
*18 years of industry &
Consulting experience*



Amrish Dixit

President
Speciality Chemicals
*22 years of industry
experience*



Chandan Singh

Co-CEO
Chemical Intermediates
*37 years of industry
experience*



Sumit Das

SVP – Nutrition &
Health Ingredients
*31 years of industry
experience*



Ashish Kumar Sinha

VP – Animal & Human
Nutrition & Health Solutions
*25 years of industry
experience*



Prakash Bisht

President &
Chief Financial Officer
*34 years of
industry experience*



Vijay Kumar Srivastava

President – Chief of
Operations
*24 years of industry
experience*



Vinita Koul

SVP & Head- HR
*27 years of industry
experience*



Prasad Joglekar

President & Head –
Supply Chain
*30 years of industry
experience*

Leadership team has an average ~ 25+ years of industry experience

Financial Highlights Q2 & H1 FY'24



Chairmen's Message on Q2'FY24 Financial Results



Mr. Shyam S Bhartia
Chairman



Mr. Hari S Bhartia
Co-Chairman

"We are pleased to announce stable business performance in Q2 & H1 of FY24, amidst the challenging market conditions.

*In the **Agrochemical sector** we have witnessed reduced volumes of the actives in the global market due to continued de-stocking of inventory. Globally prices are depressed due to increased supply from China at very low prices since the lifting of Covid-19 restrictions. This has put pressure on our agrochemicals intermediate business on both volume and prices*

*In the **Pharmaceutical end-use segment**, demand remains stable and we are witnessing good growth in our segments aligned to this sector.*

*In segments like **Food, Cosmetics and FMCG**, demand for our products remain strong. In these segments we are present through our Vitamins and other ingredients.*

Going forward, we strongly believe that Agrochemicals segment should improve from H1 next year with some green shoots by the end of Q4 FY2024. We remain confident of serving the Agrochemical sector with international agrochemical companies trying to diversify their supply chain with China plus one strategy. We are seeing many new enquiries and are currently under discussions with a few of the agrochemical companies for meeting their long-term requirements. We will continue to invest in this sector in view of the advanced discussions with some of our customers.

We continue to focus on the Pharmaceutical sector with both existing as well as new clients in order to increase our presence.

We will increase our presence through supply of ingredients in Food and Cosmetics sector from the investments already underway.

On the input costs front, we have witnessed softening of coal prices during the quarter leading to improvement in energy cost.

Indian market fundamentals remain strong with growth driven by domestic consumption across sectors, except for agrochemicals sector which is undergoing tough challenges in line with the global trends.

We remain committed to deliver structured growth in future in line with our defined capex plan."

Product Portfolio mix

- Specialty and Nutrition share increased to **53% in Q2FY24 vs. 43% in Q2FY23**
- Higher share of CDMO, Fine chemicals and Nutrition products

Green/ESG

- **Bio certification of several products** through C-14 tests
- New initiative to **increase renewable % in power usage**

Customers

- Added **78 new customers** across the business
- **Multiple long-term contracts under discussion** across acetyl, CDMO portfolio

Efficiency

- Multiple **efficiency initiatives focused on yield and energy cost** optimization through 'Surge' program

Geographic mix

- Balanced **traction from both domestic and global customers**
- Increased **traction from customers in N. American markets**

People

- **ICC Award for HR Excellence** in Chemical Industry
- Overall Gender **Diversity improved to 6.2%**

Capex plans

- Newly commissioned **Acetic Anhydride plant at Bharuch stabilized**
- **Agro actives/intermediates plant on track** for Q4FY24 commissioning

CSR

- Piloted **Integrated Voice Response System (IVRS)** for Tuberculosis monitoring
- Impacted 100K+ lives through Healthcare, Education, Livelihood support initiatives

Financial Results Overview | Consolidated

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|-----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Total Revenue | 1,304 | 1,075 | 1,020 | -5% | -22% | 2,469 | 2,095 | -18% |
| Total EBITDA | 160 | 125 | 126 | 1% | -21% | 311 | 251 | -24% |
| EBITDA Margin (%) | 12.3% | 11.6% | 12.4% | | | 12.6% | 12.0% | |
| Profit After Tax | 84 | 58 | 57 | 0% | -32% | 164 | 115 | -42% |
| Profit After Tax Margin (%) | 6.5% | 5.4% | 5.6% | | | 6.6% | 5.5% | |
| Basic and Diluted EPS (Rs.) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -42% |

- Revenue during the quarter declined due to reduction in the revenue of Chemical intermediates led by lower pass-through of input cost of acetic acid and lower demand for Agro end-use products.
- Improved overall EBITDA margin through better product mix and focus on input costs.

| Particulars ¹ | FY'2023 | Q1'FY2024 | Q2'FY2024 |
|-----------------------------|---------|-----------|-----------|
| Net Debt | 312 | 492 | 701 |
| Net Debt to Equity | 0.12x | 0.18x | 0.27x |
| Net Debt to EBITDA | 0.54x | 0.89x | 1.35x |
| Working Capital to Turnover | 17% | 20% | 23% |

- Increase in Net Debt mainly led by steady capex expenditure and higher working capital.
- Higher working capital during the quarter is on account of decline in payables for earlier purchases, while fresh purchases were rationalised.

Business Segments Overview



Market & Business Highlights | Speciality Chemicals

Market Highlights

- CDMO and Pharma end-use demand remained stable.
- Overall market situation remained challenging in Agro Chemical end-use products. Continued De-stocking and China capacities lead to higher channel Inventory.
- Muted demand due to downstream industry slow-down observed in Europe.
- Domestic demand for our products remained resilient.

Business Highlights

- Registered overall EBITDA growth and improvement in Margins owing to better product mix and higher sales contribution from Pharma, Consumer & Industrial end-use, including CDMO customers.
- CDMO business witnessed positive traction during the quarter. New projects added, which are currently in the early phase pipeline. Getting enquiries from large global customers across Pharma, Agrochemicals & Semiconductors for strategic partnership.
- Good momentum observed in Diketene range of derivatives. Plant operated at optimum capacity.
- Launched 2 new forward integrated derivative products. Pipeline of another 7-8 products under advance stage of development and commercialization.
- Under Microbial control solutions, healthy traction in Pyrithiones business coming from Paints and Coatings end usage.
- Agro active/Intermediate plant is expected to roll out as per schedule, to be commissioned in Q4 FY'24.
- Expansion of Di-ketene Derivatives is in progress. Commissioning expected towards end of FY 2024.
- Production capacity of Pyrithiones augmented at Ambernath facility for ZPTO Active manufacturing.

Business Segment Overview | Speciality Chemicals

70+ Products
(Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines; Diketene derivatives)


Globally **among Top 2** in (Pyridine+Beta);
Globally **#1** in 18 Pyridine Derivatives

Globally **lowest cost producer of Pyridine** offering significant long-term advantage


Serving **15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies**

Revenue Segmentation (Q2'FY24)

By Region



By End use



- Pharma
- Agrochemical
- Industrial
- Consumer
- Nutrition



470+ Customers Base
70+ Product Offerings



International reach through offices in US, Europe, Japan & China



Around **48%** export in regulated markets leading to sustainable revenue

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 480 | 364 | 382 | 5% | -21% | 863 | 745 | -16% |
| % Contribution to Revenues | 37% | 34% | 37% | | | 35% | 36% | |
| EBITDA | 77 | 57 | 69 | 21% | -11% | 141 | 126 | -12% |
| % EBITDA Margins | 16% | 16% | 18% | | | 16% | 17% | |
| % Contribution to EBITDA | 48% | 46% | 55% | | | 45% | 50% | |

- Business witnessed Sequential EBITDA growth during the quarter, owing to better product mix and higher sales contribution coming from Pharma and consumer end-use, including CDMO customers.
- Positive traction observed from CDMO due to recently commissioned GMP and non-GMP plants
- Witnessed reduction in overall energy cost driven by softening of coal prices and better supply mix

Market Highlights

- Vitamin demand normalised after witnessing pent-up demand in Q1.
- Downstream industries maintaining low stock level across regions due to continuous downward price movement in all the vitamins.

Business Highlights

- Nutrition & Health Ingredients (NHI) business witnessed stable demand and improved pricing in Niacinamide.
- Animal Nutrition & Health Solution (ANHS) business gained growth in volumes and continues to focus on Speciality products for future growth. Healthy traction witnessed in premixes especially in Mineral premixes, Emulsifiers, and Chromium & Herbal formulations
- Continued focus on improving volumes and share from customers in niche segments i.e. Cosmetics and Food grade.
- Capex for GMP compliant facility for expansion of Food grade Vitamin B4 is in final stages of planning.
- Enhancement of capacity for Choline & Specialty Premix products to cater to the improved demand is also under planning.

Business Segment Overview | Nutrition & Health Solutions


5 Nutrition Ingredients & 18+ branded solutions (For Animal Health)
Entered into Human Business application of Choline Chloride

Global top 2 in Vitamin B3
Domestic leader in Vitamin B4 (Feed)

Full Backward Integration for Vitamin B3 via green route


Catering to Varied End Use Industries, ranging from, Personal Care, Pharmaceuticals and Animal Feed

Niainamide End Use Applications




Revenue Segmentation (Q1'FY24)

By Region



By End use



■ Domestic ■ Exports

■ Animal Feed ■ Food ■ Cosmetics & Others*

*Personal Care & Industrial applications



“Partner of Choice” to ~460 global customers and has established strong distribution network
Globally, we serve **90+** customers in Cosmetics, **55+** Customers in Dietary supplements & **20+** Customers for Energy Drinks and Breakfast Cereals.



Around 44% exports in regulated markets leading to sustainable revenue

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 114 | 202 | 162 | -20% | 43% | 264 | 364 | 28% |
| % Contribution to Revenues | 9% | 19% | 16% | | | 11% | 17% | |
| EBITDA | 14 | 17 | 19 | 11% | 38% | 32 | 36 | 9% |
| % EBITDA Margins | 12% | 8% | 12% | | | 12% | 10% | |
| % Contribution to EBITDA | 8% | 13% | 15% | | | 10% | 14% | |

- Revenue & EBITDA grew on YoY basis, primarily led by stable demand and improved pricing in major products.

Market Highlights

- Muted demand across all the downstream industries for Agrochemicals and Paracetamol.
- Industry is maintaining low inventory levels.
- Acetic Acid price remained range-bound hovering between ~\$400/MT to \$500/MT.

Business Highlights










- Newly commissioned global scale Acetic Anhydride plant at Bharuch stabilized during the quarter.
- Business strengthened its market leadership for Acetic Anhydride in domestic as well as International market.
- Volume based contract with Global customers, towards scaling-up volumes in future.
- Witnessed realisation pressure in Acetic Anhydride on account of headwinds faced from Agrochemical end-use and paracetamol customers.
- Our new product, Bio Acetic Acid is gaining acceptance as a sustainable food preservative by major brands in India and is under approval with global customers as well. FSSAI & FSSE 22000 certifications already received.


Business Segment Overview | Chemical Intermediates

9 Products
(Acetic Anhydride, Ethyl Acetate, Propionic Anhydride, Aldehydes, Speciality Alcohol, Anhydrous Alcohol, Green Acetic Acid)

Acetic Anhydride:
Globally No. 2 in Merchant Mkt
No.1 in India
Estimated to be Global leader by FY'24

Catering to Varied End Use Industries, most of these end use having promising growth

| | | |
|---|---|--|
|  Pharmaceuticals |  Artificial Sweeteners |  Agro |
|  Cellulose Acetate |  Modified Starch |  Packaging & Coatings |
|  Polyimide Films |  Wood Acetylation |  Vitamins |



- **Catering to Multiple End Use Industries with High Growth Potential.**
- **Pharma, Agro and Packaging applications are estimated to witness strong growth, through Paracetamol, Acephate, Various APIs and Food Packaging sectors**
- **High Growth Potential through Newer End-Uses through Wood Acetylation and Polyamide Films of Mobile Phone Screen.**

Financial Highlights | Chemical Intermediates

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 710 | 509 | 476 | -6% | -33% | 1,343 | 985 | -13% |
| % Contribution to Revenues | 54% | 47% | 47% | | | 54% | 47% | |
| EBITDA | 76 | 60 | 50 | -16% | -34% | 153 | 110 | -32% |
| % EBITDA Margins | 11% | 12% | 11% | | | 11% | 11% | |
| % Contribution to EBITDA | 48% | 48% | 40% | | | 49% | 44% | |

- Lower revenue on account of lower acetic acid prices and muted market environment in Agrochemicals and Paracetamol end use customers
- Rationalized sales of Ethyl Acetate and Ethanol to maintain margin.

1. All figures are in Rs Crore unless otherwise stated



Key Strategic Initiatives

Jubilant Ingrevia Limited

Sustainability

- Conducted Biogenic Carbon Content study of our products through C-14 testing, two of the products received 100% rating and several products are 80% and above.
- Conducted Product Carbon Foot-printing (PCF) for majority of our products

RDT

- Setup a new state-of-the-art R&D lab at Greater Noida with advanced fume hoods and analytical machines, to provide world class technological and developmental support.

Digitization

- New program named 'Surge', towards enabling transformation of business processes across Manufacturing, Supply Chain & Sales through digital interventions. Multiple digital initiatives to improve our yield and efficiency.
- Implemented Data Analytics and Visualization project 'Insight' in Business processes for more efficient decision making.

Energy Efficiency

- Improve power mix towards renewable power, grid power, Power Purchase through exchange in addition to Captive generation. Share of renewable power targeted to increase to 4x by FY2028.
- Plans implemented for technological upgrades in existing as well as new production boilers to utilize biomass along with Coal.

CSR

- Healthcare: Successfully piloted IVRS system for ensuring compliances for Tuberculosis monitoring and reduce spreading of MDR Tuberculosis for 3000 plus patients. Further supported 1 Lac plus patients for healthcare needs through digital platform JUBICARE .
- Education: Created Digital Classrooms in more than 1056 schools and created 70 Micro Science Labs.
- Livelihood: Supporting 20,000 plus farmers to improve milk yields, create food orchards and good agricultural practices

Participated in S&P DJSI Assessment:

- Achieved **95 percentile** in the Global Chemical Industry
- Among the **top 5% companies globally**
- Among **top 2 Indian Chemical companies** in ESG score


- Received Gold Rating
- Achieved **93 percentile (Score 68/100)**

| Bharuch (Dec 2018) | Nira (Oct 2019) | Gajraula (Oct 2021) |
|--------------------|-----------------|---------------------|
| 157/200 (79%) | 164/200 (82%) | 186/200 (93%) |

Global chemical industry's EHS initiative & Ethical framework towards safe chemicals management and performance excellence

Climbed from 23rd to 6th position on **Responsible Business Ranking** by the joint ET-Future scope 8th Sustainability Index Report

| | |
|--------------|----|
| Climate | B |
| Water | B |
| Supply Chain | A- |



- 2001**: ISO 14000 Certification
- 2002**: Sustainability Policy Adopted
- 2003**: Sustainability Report Released
- 2005**: Became GRI Organization Stakeholder Member
- 2008**: Jubilant Bhartia Foundation CSR Wing Launched
- 2009**: Climate Change Mitigation and Green Supply Chain Policy
- 2010**: Became UNGC Signatory and Participation in CDP
- 2013**: 1st EvoVadis Review conducted
- 2015**: SoFI Sustainability Software Launched
- 2019**: Sustainability Goals created aligned with UNSDG
- 2021**: Dow Jones Sustainability Index (DJSI)

Research Development & Technology (RDT)



Newly setup R&D facility at greater Noida, equipped with state of the art technology, with advanced fume hoods and analytical machines to ensure efficient synthesis and reaction monitoring in a safer environment.



Key Highlights



3 RDT centers in Noida, Gajraula and Bharuch

35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Grignard etc.

114 highly qualified scientists (22 PhDs)

49 Products in Pipeline for next 4 years



Key Technology Platforms

| 1000s MT | | 100s MT | | | MTs | |
|-----------------------------------|-------------------|----------------|-----------------|-------------------------|-------------------------|------------------|
| Aromatization | Oxidation | Sandmeyer | Grignard | Fluorination | Hoffmann Re-arrangement | Bu-Li Reaction |
| Vapour Phase Reactions | Ammoxidation, | Bromination | Methylation | Thiol Handling | Methoxylation | Iodination |
| Chlorination / Photo chlorination | Fermentation | Esterification | Quarternisation | Ethylene Oxide Reaction | N-Formylation | Chiral Synthesis |
| | Ketene Technology | Hydrogenation | Chichibabin | | De-alkylation | |

Efficiencies through Multi Location Manufacturing & Operation Excellence

Manufacturing Facilities

463 acres



Gajraula, Uttar Pradesh, India

Integrated facility for Speciality Chemicals & Chemical Intermediates

310 acres



Bharuch, Gujarat, India

Speciality Chemicals, Nutrition & Health Ingredients & Chemical Intermediates facility located in SEZ

144 acres



Nira, Maharashtra, India

Chemical Intermediates

109 acres



Samlaya, Gujarat, India

Animal Nutrition & Health Solutions

3.5 acres



Ambernath, Maharashtra, India

Speciality Chemicals

Operation Highlights

Multi-Chemistry, Multi-Product Expertise

Continuous & Batch processes

World Class GMP facility at Bharuch

cGMP compliant Pilot Plant

Ecologically Harmonized Practices

Health & Safety benchmarking global performance

Efficiency initiatives

- Digital Twin Plants to leverage efficiency through Digital means.
- Initiatives to improve power mix towards renewable power, grid power, Power Purchase through exchange in addition to Captive generation.
- Technological upgrades in existing as well as new production boilers to utilize biomass along with Coal.

Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships

Established in 2007

Mission: To develop multi-stakeholder sustainable models to bring about 'social change' involving knowledge generation & sharing, experiential learning & entrepreneurial ecosystem



1 Million lives

Aspiring to touch the Lives through social initiatives



Education



- Benefitting over **100,000 students** in **500 govt. primary schools** through **E-Muskaan** (School Digitization), **Kushiyon Ki Pathshala** (Value education), **Muskaan Science Lab** (Science for rural children)




Improving Health



- Providing affordable basic & preventive health care to over **6.5 Lakh populations** in **437 villages** through **Jubilant Aarogya** (Providing affordable healthcare, **Swasthya Prahari** (Preventive Health care) enabled with **JUBICARE-Tele-clinic** platform)




Escalating Employability



- Working towards providing Sustainable livelihood to **10000 family** through **Nayee Disha** (Skill Development), **Samridhhi** (SHG & micro enterprise Promotion), **Jubifarm** (Sustainable Agriculture programme)




Rural Development



- Jansanchetna** : Resource mapping and disseminating Emergency Preparedness plan with neighboring community at all plant locations
- Jansuvidha Kendra**: aligning the community to government social-welfare plans
- Rural Infrastructure Support**: Supporting rural infra like Water ATM, Hand pumps, Pond reclamation, School Building, Community Toilet, etc as and when required



Social Entrepreneurship



- JBF with the **Schwab Foundation** recognize & award **exceptional individuals in Social Business**
- Providing business to social enterprises




FACE- Centre for Excellence



- An initiative between **CII & Jubilant Bhartia** to improve productivity of agriculture and increase farmer income



Annexure 1- Income Statement | Consolidated

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | QoQ | YoY | H1'FY23 | H1'FY24 | YoY |
|--|-------------|-------------|-------------|------------|--------------|-------------|-------------|--------------|
| Revenue from operations | | | | | | | | |
| a) Sales/Income from operations | 1299 | 1069 | 1011 | -5% | -22% | 2458 | 2080 | -15% |
| b) Other operating income | 5 | 6 | 9 | 39% | 92% | 11 | 15 | 38% |
| Total revenue from operations | 1304 | 1075 | 1020 | -5% | -22% | 2469 | 2095 | -15% |
| Other income | 7 | 9 | 9 | 0% | 17% | 17 | 17 | -2% |
| Total income | 1311 | 1084 | 1028 | -5% | -22% | 2487 | 2112 | -15% |
| Expenses | | | | | | | | |
| a) Cost of materials consumed | 702 | 579 | 473 | -18% | -33% | 1386 | 1052 | -24% |
| b) Purchases of stock-in-trade | 37 | 21 | 14 | -32% | -61% | 74 | 35 | -53% |
| c) Changes in inventories of finished goods, stock-in-trade and work-in progress | -24 | -50 | 18 | -137% | -177% | -136 | -31 | -77% |
| d) Employee benefits expense | 93 | 93 | 103 | 11% | 11% | 175 | 197 | 12% |
| e) Finance costs | 5 | 11 | 13 | 9% | 145% | 9 | 24 | 161% |
| f) Depreciation and amortisation expense | 31 | 32 | 34 | 5% | 9% | 62 | 66 | 6% |
| g) Other expenses: | | | | | | | | |
| - Power and fuel expense | 188 | 159 | 133 | -16% | -29% | 380 | 293 | -23% |
| - Others | 155 | 155 | 160 | 3% | 3% | 297 | 316 | 6% |
| Total expenses | 1187 | 1002 | 949 | -5% | -20% | 2247 | 1951 | -13% |
| Profit before share of loss of an associate (3-4) | 124 | 81 | 80 | -2% | -36% | 240 | 161 | -33% |
| Share of loss of an associate | 0 | 0 | 0 | | -400% | 0 | 0 | -200% |
| Profit before tax | 124 | 81 | 80 | -2% | -36% | 240 | 161 | -33% |
| Tax expense | | | | | | | | |
| - Current tax | 23 | 17 | 13 | -25% | -46% | 48 | 29 | -39% |
| - Deferred tax charge | 16 | 7 | 10 | 40% | -41% | 28 | 17 | -40% |
| Net profit for the period/year | 84 | 58 | 57 | 0% | -32% | 164 | 115 | -30% |
| Earnings per share of ₹ 1 each | | | | | | | | |
| Basic (₹) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -29% |
| Diluted (₹) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -29% |

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

Annexure II: Income Statement Segmental – Q1 & H1'FY24

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | QoQ (%) | YoY (%) | H1'FY23 | H1'FY24 | YoY (%) |
|---|--------------|--------------|--------------|-------------|--------------|--------------|--------------|--------------|
| Total Revenue from Operations | 1,304 | 1,075 | 1,020 | (5%) | (22%) | 2,469 | 2,095 | (15%) |
| Speciality Chemicals | 480 | 364 | 382 | 5% | (21%) | 863 | 745 | (14%) |
| Nutrition & Health Solutions | 114 | 202 | 162 | (20%) | 43% | 264 | 364 | 38% |
| Chemical Intermediates | 710 | 509 | 476 | (6%) | (33%) | 1,343 | 985 | (27%) |
| Reported EBITDA | 160 | 125 | 126 | 1% | (21%) | 311 | 251 | (19%) |
| Speciality Chemicals | 77 | 57 | 69 | 21% | (11%) | 141 | 126 | (11%) |
| Nutrition & Health Solutions | 14 | 17 | 19 | 11% | 38% | 32 | 36 | 10% |
| Chemical Intermediates | 76 | 60 | 50 | (16%) | (34%) | 153 | 110 | (28%) |
| Unallocated Corporate (Expenses)/Income | -7 | -9 | -12 | - | - | -15 | -20 | - |
| PAT | 84 | 58 | 57 | (0%) | (32%) | 164 | 115 | (30%) |
| EPS | 5.3 | 3.6 | 3.6 | 0% | (31%) | 10.3 | 7.3 | (29%) |
| Reported EBITDA Margins | 12.3% | 11.6% | 12.4% | | | 12.6% | 12.0% | |
| Speciality Chemicals | 16.0% | 15.7% | 18.1% | | | 16.4% | 16.9% | |
| Nutrition & Health Solutions | 11.9% | 8.3% | 11.5% | | | 12.2% | 9.8% | |
| Chemical Intermediates | 10.8% | 11.8% | 10.6% | | | 11.4% | 11.2% | |
| Net Margin | 6.5% | 5.4% | 5.6% | | | 6.6% | 5.5% | |

1. All figures are in Rs Crore unless otherwise stated.

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has over 2,300 employees and serves more than 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia Limited is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: www.jubilantingrevia.com

For Investors:

Pavleen Taneja

Jubilant Ingrevia Limited.

☎ Ph: +91 120 436 1000

✉ E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India

☎ Ph: +91 22 6645 1209

✉ E-mail: siddharth@cdr-india.com

For Media:

Sudhakar Safaya

☎ Ph: +91 120 436 1034

✉ E-mail: sudhakar.safaya@jubl.com

Ryan Marshall


Madison Public Relations

☎ Ph: +91 9810047944

✉ E-mail: ryan.marshall@madisonpr.in

Annexure III - Conference Call Details

Date : November 01st, 2023
Time : 05:00 pm IST

| Diamond Pass Log-In | |
|----------------------------|---|
| Pre-registration: | <p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <div style="text-align: center;">  Click here to ExpressJoin the Call </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p> |
| Conference Dial-In Numbers | |
| Universal Access: | <p>+ 91 22 6280 1141 + 91 22 7115 8042</p> |
| Toll Free Number: | <p>USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448</p> |
| Audio Link: | <p>The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly-results</p> |



Jubilant Ingrevia Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantingrevia.com

PRESS RELEASE

Noida, Wednesday, November 01st, 2023

JUBILANT INGREVIA LIMITED – Q2 & H1'FY24 RESULTS

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|-----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Total Revenue | 1,304 | 1,075 | 1,020 | -5% | -22% | 2,469 | 2,095 | -18% |
| Total EBITDA | 160 | 125 | 126 | 1% | -21% | 311 | 251 | -24% |
| EBITDA Margin (%) | 12.3% | 11.6% | 12.4% | | | 12.6% | 12.0% | |
| Profit After Tax | 84 | 58 | 57 | 0% | -32% | 164 | 115 | -42% |
| Profit After Tax Margin (%) | 6.5% | 5.4% | 5.6% | | | 6.6% | 5.5% | |
| Basic and Diluted EPS (Rs.) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -42% |

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter and half year ended September 30th, 2023.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

"We are pleased to announce stable business performance in Q2 & H1 of FY24, amidst the challenging market conditions.

*In the **Agrochemical sector** we have witnessed reduced volumes of the actives in the global market due to continued de-stocking of inventory. Globally prices are depressed due to increased supply from China at very low prices since the lifting of Covid-19 restrictions. This has put pressure on our agrochemicals intermediate business on both volume and prices*

*In the **Pharmaceutical end-use segment**, demand remains stable and we are witnessing good growth in our segments aligned to this sector.*

*In segments like **Food, Cosmetics and FMCG**, demand for our products remain strong. In these segments we are present through our Vitamins and other ingredients.*

Going forward, we strongly believe that Agrochemicals segment should improve from H1 next year with some green shoots by the end of Q4 FY2024. We remain confident of serving the Agrochemical sector with international agrochemical companies trying to diversify their supply chain with China plus one strategy. We are seeing many new enquiries and are currently under discussions with a few of the agrochemical companies for meeting their long-term requirements. We will continue to invest in this sector in view of the advanced discussions with some of our customers.

We continue to focus on the Pharmaceutical sector with both existing as well as new clients in order to increase our presence.

We will increase our presence through supply of ingredients in Food and Cosmetics sector from the investments already underway.

On the input costs front, we have witnessed softening of coal prices during the quarter leading to improvement in energy cost.

Indian market fundamentals remain strong with growth driven by domestic consumption across sectors, except for agrochemicals sector which is undergoing tough challenges in line with the global trends.

We remain committed to deliver structured growth in future in line with our defined capex plan."



Q2 & H1'FY24 Highlights | Segment Wise Analysis

A. Speciality Chemicals

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 480 | 364 | 382 | 5% | -21% | 863 | 745 | -16% |
| % Contribution to Revenues | 37% | 34% | 37% | | | 35% | 36% | |
| EBITDA | 77 | 57 | 69 | 21% | -11% | 141 | 126 | -12% |
| % EBITDA Margins | 16% | 16% | 18% | | | 16% | 17% | |
| % Contribution to EBITDA | 48% | 46% | 55% | | | 45% | 50% | |

- Registered overall EBITDA growth and improvement in Margins owing to better product mix and higher sales contribution from Pharma, Consumer & Industrial end-use, including CDMO customers.
- CDMO business witnessed positive traction during the quarter. New projects added, which are currently in the early phase pipeline. Getting enquiries from large global customers across Pharma, Agrochemicals & Semiconductors for strategic partnership.
- Good momentum observed in Diketene range of derivatives. Plant operated at optimum capacity.
- Launched 2 new forward integrated derivative products. Pipeline of another 7-8 products under advance stage of development and commercialization.
- Under Microbial control solutions, healthy traction in Pyrithiones business coming from Paints and Coatings end usage.
- Agro active/Intermediate plant is expected to roll out as per schedule, to be commissioned in Q4 FY'24.
- Expansion of Di-ketene Derivatives is in progress. Commissioning expected towards end of FY 2024.
- Production capacity of Pyrithiones augmented at Ambernath facility for ZPTO Active manufacturing.

B. Nutrition & Health Solutions

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 114 | 202 | 162 | -20% | 43% | 264 | 364 | 28% |
| % Contribution to Revenues | 9% | 19% | 16% | | | 11% | 17% | |
| EBITDA | 14 | 17 | 19 | 11% | 38% | 32 | 36 | 9% |
| % EBITDA Margins | 12% | 8% | 12% | | | 12% | 10% | |
| % Contribution to EBITDA | 8% | 13% | 15% | | | 10% | 14% | |

- Nutrition & Health Ingredients (NHI) business witnessed stable demand and improved pricing in Niacinamide.
- Animal Nutrition & Health Solution (ANHS) business gained growth in volumes and continues to focus on Speciality products for future growth. Healthy traction witnessed in premixes especially in Mineral premixes, Emulsifiers, and Chromium & Herbal formulations
- Continued focus on improving volumes and share from customers in niche segments i.e. Cosmetics and Food grade.
- Capex for GMP compliant facility for expansion of Food grade Vitamin B4 is in final stages of planning.
- Enhancement of capacity for Choline & Specialty Premix products to cater to the improved demand is also under planning.

1. All figures are in Rs Crore unless otherwise stated

C. Chemical Intermediates Segment

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | Q-o-Q | Y-o-Y | H1'FY23 | H1'FY24 | Y-o-Y |
|----------------------------|---------|---------|---------|-------|-------|---------|---------|-------|
| Segment Revenues | 710 | 509 | 476 | -6% | -33% | 1,343 | 985 | -13% |
| % Contribution to Revenues | 54% | 47% | 47% | | | 54% | 47% | |
| EBITDA | 76 | 60 | 50 | -16% | -34% | 153 | 110 | -32% |
| % EBITDA Margins | 11% | 12% | 11% | | | 11% | 11% | |
| % Contribution to EBITDA | 48% | 48% | 40% | | | 49% | 44% | |

- Newly commissioned global scale Acetic Anhydride plant at Bharuch stabilized during the quarter.
- Business strengthened its market leadership for Acetic Anhydride in domestic as well as International market.
- Volume based contract with Global customers, towards scaling-up volumes in future.
- Witnessed realisation pressure in Acetic Anhydride on account of headwinds faced from Agrochemical end-use and paracetamol customers.
- Our new product, Bio Acetic Acid is gaining acceptance as a sustainable food preservative by major brands in India and is under approval with global customers as well. FSSAI & FSSE 22000 certifications already received.

D. Income Statement – Q2 & H1'FY24

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | QoQ | YoY | H1'FY23 | H1'FY24 | YoY |
|--|-------------|-------------|-------------|------------|--------------|-------------|-------------|--------------|
| Revenue from operations | | | | | | | | |
| a) Sales/Income from operations | 1299 | 1069 | 1011 | -5% | -22% | 2458 | 2080 | -15% |
| b) Other operating income | 5 | 6 | 9 | 39% | 92% | 11 | 15 | 38% |
| Total revenue from operations | 1304 | 1075 | 1020 | -5% | -22% | 2469 | 2095 | -15% |
| Other income | 7 | 9 | 9 | 0% | 17% | 17 | 17 | -2% |
| Total income | 1311 | 1084 | 1028 | -5% | -22% | 2487 | 2112 | -15% |
| Expenses | | | | | | | | |
| a) Cost of materials consumed | 702 | 579 | 473 | -18% | -33% | 1386 | 1052 | -24% |
| b) Purchases of stock-in-trade | 37 | 21 | 14 | -32% | -61% | 74 | 35 | -53% |
| c) Changes in inventories of finished goods, stock-in-trade and work-in progress | -24 | -50 | 18 | -137% | -177% | -136 | -31 | -77% |
| d) Employee benefits expense | 93 | 93 | 103 | 11% | 11% | 175 | 197 | 12% |
| e) Finance costs | 5 | 11 | 13 | 9% | 145% | 9 | 24 | 161% |
| f) Depreciation and amortisation expense | 31 | 32 | 34 | 5% | 9% | 62 | 66 | 6% |
| g) Other expenses: | | | | | | | | |
| - Power and fuel expense | 188 | 159 | 133 | -16% | -29% | 380 | 293 | -23% |
| - Others | 155 | 155 | 160 | 3% | 3% | 297 | 316 | 6% |
| Total expenses | 1187 | 1002 | 949 | -5% | -20% | 2247 | 1951 | -13% |
| Profit before share of loss of an associate (3-4) | 124 | 81 | 80 | -2% | -36% | 240 | 161 | -33% |
| Share of loss of an associate | 0 | 0 | 0 | | -400% | 0 | 0 | -200% |
| Profit before tax | 124 | 81 | 80 | -2% | -36% | 240 | 161 | -33% |
| Tax expense | | | | | | | | |
| - Current tax | 23 | 17 | 13 | -25% | -46% | 48 | 29 | -39% |
| - Deferred tax charge | 16 | 7 | 10 | 40% | -41% | 28 | 17 | -40% |
| Net profit for the period/year | 84 | 58 | 57 | 0% | -32% | 164 | 115 | -30% |
| Earnings per share of ₹ 1 each | | | | | | | | |
| Basic (₹) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -29% |
| Diluted (₹) | 5.3 | 3.6 | 3.6 | 0% | -31% | 10.3 | 7.3 | -29% |

1. All figures are in Rs Crore unless otherwise stated



E. Segment P&L – Q2 & H1'FY24

| Particulars ¹ | Q2'FY23 | Q1'FY24 | Q2'FY24 | QoQ (%) | YoY (%) | H1'FY23 | H1'FY24 | YoY (%) |
|---|--------------|--------------|--------------|-------------|--------------|--------------|--------------|--------------|
| Total Revenue from Operations | 1,304 | 1,075 | 1,020 | (5%) | (22%) | 2,469 | 2,095 | (15%) |
| Speciality Chemicals | 480 | 364 | 382 | 5% | (21%) | 863 | 745 | (14%) |
| Nutrition & Health Solutions | 114 | 202 | 162 | (20%) | 43% | 264 | 364 | 38% |
| Chemical Intermediates | 710 | 509 | 476 | (6%) | (33%) | 1,343 | 985 | (27%) |
| Reported EBITDA | 160 | 125 | 126 | 1% | (21%) | 311 | 251 | (19%) |
| Speciality Chemicals | 77 | 57 | 69 | 21% | (11%) | 141 | 126 | (11%) |
| Nutrition & Health Solutions | 14 | 17 | 19 | 11% | 38% | 32 | 36 | 10% |
| Chemical Intermediates | 76 | 60 | 50 | (16%) | (34%) | 153 | 110 | (28%) |
| Unallocated Corporate (Expenses)/Income | -7 | -9 | -12 | - | - | -15 | -20 | - |
| PAT | 84 | 58 | 57 | (0%) | (32%) | 164 | 115 | (30%) |
| EPS | 5.3 | 3.6 | 3.6 | 0% | (31%) | 10.3 | 7.3 | (29%) |
| Reported EBITDA Margins | 12.3% | 11.6% | 12.4% | | | 12.6% | 12.0% | |
| Speciality Chemicals | 16.0% | 15.7% | 18.1% | | | 16.4% | 16.9% | |
| Nutrition & Health Solutions | 11.9% | 8.3% | 11.5% | | | 12.2% | 9.8% | |
| Chemical Intermediates | 10.8% | 11.8% | 10.6% | | | 11.4% | 11.2% | |
| Net Margin | 6.5% | 5.4% | 5.6% | | | 6.6% | 5.5% | |

F. Key Ratios

| Particulars ¹ | FY'2023 | Q1'FY2024 | Q2'FY2024 |
|-----------------------------|---------|-----------|-----------|
| Net Debt | 312 | 492 | 701 |
| Net Debt to Equity | 0.12x | 0.18x | 0.27x |
| Net Debt to EBITDA | 0.54x | 0.89x | 1.35x |
| Working Capital to Turnover | 17% | 20% | 23% |

- Increase in Net Debt mainly led by steady capex expenditure and higher working capital.
- Higher working capital during the quarter is on account of decline in payables for earlier purchases, while fresh purchases were rationalised.

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has over 2,300 employees and serves more than 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: www.jubilantingrevia.com.

1. All figures are in Rs Crore unless otherwise stated



For more information, please contact:

For Investors

Pavleen Taneja
Jubilant Ingrevia Limited
Ph: +91-120 436 1000
E-mail: pavleen.taneja@jubl.com


Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya
Ph: +91-120 436 1062
E-mail: sudhakar.safaya@jubl.com

Ryan Marshall
Madison Public Relations
E-mail: ryan.marshall@madisonpr.in
Ph: +91 9810047944

Earnings Call details: The company will host earnings call at 5.00 PM IST on 1st November, 2023

| Diamond Pass Log-In | |
|-----------------------------------|---|
| Pre-registration: | <p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p>  <p>Click here to ExpressJoin the Call</p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p> |
| Conference Dial-In Numbers | |
| Universal Access: | + 91 22 6280 1141 + 91 22 7115 8042 |
| Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
| Audio Link: | The Audio link will be available on the company website. Please access the link here - |
| Disclaimer: | https://jubilantingrevia.com/investors/financials/quarterly-results |

Note 1

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.